Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
P Brooks, P Emery, JF Evans, H Fenner, CJ Hawkey, C Patrono, J Smolen, F Breedveld, R Day, M Dougados, EW Ehrich, J Gijon-Baños, TK Kvien, MH Van Rijswijk, T Warner, H Zeidler
Rheumatology (Oxford) | Published : 1999
The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5 6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no ..View full abstract